studied industrial engineering at the Technical University of Berlin and the Royal Institute of Technology in Stockholm (Sweden). He has been working at the IGES Institute since 2015 and heads the Value & Access Strategy department. His work focuses on strategic advice on issues of market access, early benefit assessment and health economics issues. His research focus is on national/international drug regulation issues.